凝血酶激活纤溶抑制物散射比浊法检测结果临床应用评估

The feasibility of clinical application for plasma TAFI determined by rate nephelometry assay

目的初步评估纤溶抑制物(TAFI)免疫速率散射比浊法检测结果在临床应用的可行性。方法收集临床治疗中需要监测凝血功能变化的多种疾病患者,包括冠心病、肿瘤、感染性疾病、肾病、缺血性脑血管病、自身免疫性相关皮肤病、肝硬化、深静脉血栓形成等疾病共计677例。采用免疫速率散射比浊法检测患者血浆TAFI浓度。结果 677例患者血浆TAFI浓度值与PT、APTT检测值呈负相关,与FIB含量呈正相关,与D-二聚体无显著相关性。与健康对照组比较,677例患者血浆TAFI浓度显著降低,尤其是冠心病、肿瘤、感染等疾病的血浆TAFI浓度较对照组显著下降(P<0.01)。结论 TAFI免疫速率散射比浊检测法可用于凝血功能改变相关疾病的诊治、病情的监测及预后的判断。

Objective To assess the feasibility of clinical application for plasma TAFI determined by rate nephelometry assay. Methods To collect serum of patiants with monitoring changes of coagulation in a variety of diseases,including coronary heart disease,cancer,infectious diseases,kidney disease,ischemic cerebrovascular disease,dermatology and autoimmune related disease,liver cirrhosis,deep vein thrombosis and other diseases totaled 677 cases. Plasma concentrations of TAFI in patients determined by rate nephelometry assay. Results TAFI plasma concentration in patients with PT,APTT detection value was negatively correlated positively with FIB content,and was not significantly correlated with D-dimer. Compared with the healthy control group,TAFI concentration of 677 cases of patients with plasma was significantly reduced（ P〈0. 01）,especially in these patients with coronary heart disease,tumor,infections and other diseases. Conclusion Conclusion The TAFI results determined by rate nephelometry assay may reflect changes in condition clinically relevant disease. It is a potential biological marker for disease prevention,monitoring and prognosis.